Cargando…
A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells
BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959055/ https://www.ncbi.nlm.nih.gov/pubmed/27458481 http://dx.doi.org/10.1186/s13065-016-0191-y |
_version_ | 1782444364618792960 |
---|---|
author | Qiu, Chao Gao, Li-Na Yan, Kuo Cui, Yuan-Lu Zhang, Ye |
author_facet | Qiu, Chao Gao, Li-Na Yan, Kuo Cui, Yuan-Lu Zhang, Ye |
author_sort | Qiu, Chao |
collection | PubMed |
description | BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine/hydroxypropyl-β-cyclodextrin (EVO/HP-β-CD) inclusion complex, which is incorporated evodiamine into HP-β-CD, and compare the antitumor activities before and after inclusion with HP-β-CD in human hepatoma HepG2 cells. RESULTS: The EVO/HP-β-CD inclusion complexes were prepared by the kneading method and structurally characterized. P-glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P-glycoprotein, while HP-β-CD and EVO/HP-β-CD inclusion complexes inhibited P-glycoprotein by blocking P-glycoprotein ATPase activity. The EVO/HP-β-CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. After given evodiamine or EVO/HP-β-CD inclusion complexes intervention, cell viability evaluation indicated that the half inhibition concentration of evodiamine and EVO/HP-β-CD inclusion complexes on HepG2 cells was 8.516 and 0.977 μM, respectively. The caspase-3 enzyme activity analysis and Annexin V/PI double-staining revealed that EVO/HP-β-CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay demonstrated that EVO/HP-β-CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine. CONCLUSIONS: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and P-glycoprotein inhibition by HP-β-CD. These results are promising for the drug administration of EVO/HP-β-CD inclusion complexes to enhance the bioavailability of evodiamine in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13065-016-0191-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4959055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-49590552016-07-26 A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells Qiu, Chao Gao, Li-Na Yan, Kuo Cui, Yuan-Lu Zhang, Ye Chem Cent J Research Article BACKGROUND: Evodiamine has gained wide interests recently because of its antitumor activities. However, a superior bioavailability is required to achieve better efficacy due to its poor water solubility. The aim of this study was to enhance the evodiamine’s aqueous solubility by preparing evodiamine/hydroxypropyl-β-cyclodextrin (EVO/HP-β-CD) inclusion complex, which is incorporated evodiamine into HP-β-CD, and compare the antitumor activities before and after inclusion with HP-β-CD in human hepatoma HepG2 cells. RESULTS: The EVO/HP-β-CD inclusion complexes were prepared by the kneading method and structurally characterized. P-glycoprotein ATPase assays firstly demonstrated that evodiamine was a substrate of P-glycoprotein, while HP-β-CD and EVO/HP-β-CD inclusion complexes inhibited P-glycoprotein by blocking P-glycoprotein ATPase activity. The EVO/HP-β-CD inclusion complexes may be a promising anticancer drug candidate without drug resistance. After given evodiamine or EVO/HP-β-CD inclusion complexes intervention, cell viability evaluation indicated that the half inhibition concentration of evodiamine and EVO/HP-β-CD inclusion complexes on HepG2 cells was 8.516 and 0.977 μM, respectively. The caspase-3 enzyme activity analysis and Annexin V/PI double-staining revealed that EVO/HP-β-CD inclusion complexes possessed better antitumor activities than evodiamine. Additionally, Hoechst 33258 staining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay demonstrated that EVO/HP-β-CD inclusion complexes induced HepG2 cell apoptosis more effectively than evodiamine. CONCLUSIONS: The improved antitumor activities of evodiamine were attributed to the enhanced solubility and P-glycoprotein inhibition by HP-β-CD. These results are promising for the drug administration of EVO/HP-β-CD inclusion complexes to enhance the bioavailability of evodiamine in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13065-016-0191-y) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-07-25 /pmc/articles/PMC4959055/ /pubmed/27458481 http://dx.doi.org/10.1186/s13065-016-0191-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Qiu, Chao Gao, Li-Na Yan, Kuo Cui, Yuan-Lu Zhang, Ye A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title | A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title_full | A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title_fullStr | A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title_full_unstemmed | A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title_short | A promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma HepG2 cells |
title_sort | promising antitumor activity of evodiamine incorporated in hydroxypropyl-β-cyclodextrin: pro-apoptotic activity in human hepatoma hepg2 cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959055/ https://www.ncbi.nlm.nih.gov/pubmed/27458481 http://dx.doi.org/10.1186/s13065-016-0191-y |
work_keys_str_mv | AT qiuchao apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT gaolina apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT yankuo apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT cuiyuanlu apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT zhangye apromisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT qiuchao promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT gaolina promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT yankuo promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT cuiyuanlu promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells AT zhangye promisingantitumoractivityofevodiamineincorporatedinhydroxypropylbcyclodextrinproapoptoticactivityinhumanhepatomahepg2cells |